Development of Prodrug 4-Chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl Benzoate (TG100801) : A Topically Administered Therapeutic Candidate in Clinical Trials for the Treatment of Age-Related Macular Degeneration.
Purbey PK, Singh S, Notani D, Kumar PP, Limaye AS, Galande S. Acetylation-dependent interaction of SATB1 and CtBP1 mediates transcriptional repression by SATB1. Mol Cell Biol. 2009;29(5):1321-37.
Chattopadhyay I, Kapur S, Purkayastha J, et al. Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis. World J Gastroenterol. 2007;13(9):1438-44.
Jalota-badhwar A, Kaul-ghanekar R, Mogare D, Boppana R, Paknikar KM, Chattopadhyay S. SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53. J Biol Chem. 2007;282(13):9902-13.
Mantelingu K, Reddy BA, Swaminathan V, et al. Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol. 2007;14(6):645-57.
Chattopadhyay I, Kapur S, Purkayastha J, et al. Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis. World J Gastroenterol. 2007;13(9):1438-44.
Singh K, Mogare D, Giridharagopalan RO, Gogiraju R, Pande G, Chattopadhyay S. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion. PLoS ONE. 2007;2(7):e660.
Noronha G, Barrett K, Boccia A, et al. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine–a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg Med Chem Lett. 2007;17(3):602-8.
Targeting Drug Resistant Mutations Using Novel Binding Interactions – Lessons Learned from Abl-T315I and their Implications in Drug Design . Frontiers in Drug Design & Discovery: Structure-Based Drug Design in the 21st Century